Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02142803 · OUTCOME

Overall Survival (OS)

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 4 years

What was measured

Overall Survival (OS) listed for all patients by dose level.

Analysis population: * Given the limited sample sizes for Dose Levels 1 \& 2 (3 \& 2 patients respectively), the #s presented here may not be statistically valid. * Censoring \& Final OS #s: 1 patient treated at Dose Level 2 and 6 patients treated at Dose Level 3 were censored from OS analysis for withdrawal of consent or lost to follow-up, and were not followed for survival to their death.

Groups in this outcome

Dose Level 1

3 mg/day MLN0128

Dose Level 2

4 mg/day MLN0128

Dose Level 3 (MTD)

5 mg/day MLN0128

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 13
Dose Level 22
Dose Level 3 (MTD)36

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose Level 17.9Not reported2.0NASample size of 3 patients is too small.
Dose Level 211.6Not reported3.7NASample size of 2 patients is too small.
Dose Level 3 (MTD)9.3Not reported6.013.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Sample size of 3 patients is too small.
        group Id
        OG000
        lower Limit
        2.0
        upper Limit
        NA
        value
        7.9
      2. comment
        Sample size of 2 patients is too small.
        group Id
        OG001
        lower Limit
        3.7
        upper Limit
        NA
        value
        11.6
      3. group Id
        OG002
        lower Limit
        6.0
        upper Limit
        13.5
        value
        9.3
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      36
    units
    Participants
description
Overall Survival (OS) listed for all patients by dose level.
dispersion Type
95% Confidence Interval
groups
  1. description
    3 mg/day MLN0128
    id
    OG000
    title
    Dose Level 1
  2. description
    4 mg/day MLN0128
    id
    OG001
    title
    Dose Level 2
  3. description
    5 mg/day MLN0128
    id
    OG002
    title
    Dose Level 3 (MTD)
param Type
MEDIAN
population Description
* Given the limited sample sizes for Dose Levels 1 \& 2 (3 \& 2 patients respectively), the #s presented here may not be statistically valid. * Censoring \& Final OS #s: 1 patient treated at Dose Level 2 and 6 patients treated at Dose Level 3 were censored from OS analysis for withdrawal of consent or lost to follow-up, and were not followed for survival to their death.
reporting Status
POSTED
time Frame
Up to 4 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice